line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,POLYMED.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.251832,POLYMED.NS
Normalized EBITDA,2025-03-31 00:00:00,5476938000.0,POLYMED.NS
Total Unusual Items,2025-03-31 00:00:00,0.0,POLYMED.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,0.0,POLYMED.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,3385572000.0,POLYMED.NS
Reconciled Depreciation,2025-03-31 00:00:00,831822000.0,POLYMED.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,5546902000.0,POLYMED.NS
EBITDA,2025-03-31 00:00:00,5476938000.0,POLYMED.NS
EBIT,2025-03-31 00:00:00,4645116000.0,POLYMED.NS
Net Interest Income,2025-03-31 00:00:00,-119965000.0,POLYMED.NS
Interest Expense,2025-03-31 00:00:00,119965000.0,POLYMED.NS
Interest Income,2025-03-31 00:00:00,,POLYMED.NS
Normalized Income,2025-03-31 00:00:00,3385572000.0,POLYMED.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,3385572000.0,POLYMED.NS
Total Expenses,2025-03-31 00:00:00,12996277000.0,POLYMED.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,POLYMED.NS
Diluted Average Shares,2025-03-31 00:00:00,,POLYMED.NS
Basic Average Shares,2025-03-31 00:00:00,,POLYMED.NS
Diluted EPS,2025-03-31 00:00:00,,POLYMED.NS
Basic EPS,2025-03-31 00:00:00,,POLYMED.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,3385572000.0,POLYMED.NS
Net Income Common Stockholders,2025-03-31 00:00:00,3385572000.0,POLYMED.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,POLYMED.NS
Net Income,2025-03-31 00:00:00,3385572000.0,POLYMED.NS
Minority Interests,2025-03-31 00:00:00,,POLYMED.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,3385572000.0,POLYMED.NS
Net Income Continuous Operations,2025-03-31 00:00:00,3385572000.0,POLYMED.NS
Tax Provision,2025-03-31 00:00:00,1139579000.0,POLYMED.NS
Pretax Income,2025-03-31 00:00:00,4525151000.0,POLYMED.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,891276000.0,POLYMED.NS
Special Income Charges,2025-03-31 00:00:00,0.0,POLYMED.NS
Other Special Charges,2025-03-31 00:00:00,,POLYMED.NS
Write Off,2025-03-31 00:00:00,,POLYMED.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-119965000.0,POLYMED.NS
Total Other Finance Cost,2025-03-31 00:00:00,,POLYMED.NS
Interest Expense Non Operating,2025-03-31 00:00:00,119965000.0,POLYMED.NS
Interest Income Non Operating,2025-03-31 00:00:00,,POLYMED.NS
Operating Income,2025-03-31 00:00:00,3702039000.0,POLYMED.NS
Operating Expense,2025-03-31 00:00:00,7449375000.0,POLYMED.NS
Other Operating Expenses,2025-03-31 00:00:00,3361984000.0,POLYMED.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,826360000.0,POLYMED.NS
Amortization,2025-03-31 00:00:00,,POLYMED.NS
Depreciation Income Statement,2025-03-31 00:00:00,826360000.0,POLYMED.NS
Research And Development,2025-03-31 00:00:00,245711000.0,POLYMED.NS
Selling General And Administration,2025-03-31 00:00:00,,POLYMED.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,POLYMED.NS
General And Administrative Expense,2025-03-31 00:00:00,,POLYMED.NS
Rent And Landing Fees,2025-03-31 00:00:00,,POLYMED.NS
Gross Profit,2025-03-31 00:00:00,11151414000.0,POLYMED.NS
Cost Of Revenue,2025-03-31 00:00:00,5546902000.0,POLYMED.NS
Total Revenue,2025-03-31 00:00:00,16698316000.0,POLYMED.NS
Operating Revenue,2025-03-31 00:00:00,16698316000.0,POLYMED.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,POLYMED.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.249832,POLYMED.NS
Normalized EBITDA,2024-03-31 00:00:00,4194965000.0,POLYMED.NS
Total Unusual Items,2024-03-31 00:00:00,0.0,POLYMED.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,0.0,POLYMED.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,2582597000.0,POLYMED.NS
Reconciled Depreciation,2024-03-31 00:00:00,639265000.0,POLYMED.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,4826076000.0,POLYMED.NS
EBITDA,2024-03-31 00:00:00,4194965000.0,POLYMED.NS
EBIT,2024-03-31 00:00:00,3555700000.0,POLYMED.NS
Net Interest Income,2024-03-31 00:00:00,-113009000.0,POLYMED.NS
Interest Expense,2024-03-31 00:00:00,113009000.0,POLYMED.NS
Interest Income,2024-03-31 00:00:00,118356000.0,POLYMED.NS
Normalized Income,2024-03-31 00:00:00,2582597000.0,POLYMED.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,2582597000.0,POLYMED.NS
Total Expenses,2024-03-31 00:00:00,10815012000.0,POLYMED.NS
Rent Expense Supplemental,2024-03-31 00:00:00,22265000.0,POLYMED.NS
Diluted Average Shares,2024-03-31 00:00:00,96007323.0,POLYMED.NS
Basic Average Shares,2024-03-31 00:00:00,95935996.0,POLYMED.NS
Diluted EPS,2024-03-31 00:00:00,26.9,POLYMED.NS
Basic EPS,2024-03-31 00:00:00,26.92,POLYMED.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,2582597000.0,POLYMED.NS
Net Income Common Stockholders,2024-03-31 00:00:00,2582597000.0,POLYMED.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,POLYMED.NS
Net Income,2024-03-31 00:00:00,2582597000.0,POLYMED.NS
Minority Interests,2024-03-31 00:00:00,0.0,POLYMED.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,2582597000.0,POLYMED.NS
Net Income Continuous Operations,2024-03-31 00:00:00,2582597000.0,POLYMED.NS
Tax Provision,2024-03-31 00:00:00,860094000.0,POLYMED.NS
Pretax Income,2024-03-31 00:00:00,3442691000.0,POLYMED.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,587481000.0,POLYMED.NS
Special Income Charges,2024-03-31 00:00:00,0.0,POLYMED.NS
Other Special Charges,2024-03-31 00:00:00,-6228000.0,POLYMED.NS
Write Off,2024-03-31 00:00:00,11827000.0,POLYMED.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-113009000.0,POLYMED.NS
Total Other Finance Cost,2024-03-31 00:00:00,28647000.0,POLYMED.NS
Interest Expense Non Operating,2024-03-31 00:00:00,113009000.0,POLYMED.NS
Interest Income Non Operating,2024-03-31 00:00:00,118356000.0,POLYMED.NS
Operating Income,2024-03-31 00:00:00,2942951000.0,POLYMED.NS
Operating Expense,2024-03-31 00:00:00,5988936000.0,POLYMED.NS
Other Operating Expenses,2024-03-31 00:00:00,2700952000.0,POLYMED.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,634444000.0,POLYMED.NS
Amortization,2024-03-31 00:00:00,34911000.0,POLYMED.NS
Depreciation Income Statement,2024-03-31 00:00:00,634444000.0,POLYMED.NS
Research And Development,2024-03-31 00:00:00,194423000.0,POLYMED.NS
Selling General And Administration,2024-03-31 00:00:00,473246000.0,POLYMED.NS
Selling And Marketing Expense,2024-03-31 00:00:00,263654000.0,POLYMED.NS
General And Administrative Expense,2024-03-31 00:00:00,209592000.0,POLYMED.NS
Rent And Landing Fees,2024-03-31 00:00:00,22265000.0,POLYMED.NS
Gross Profit,2024-03-31 00:00:00,8931887000.0,POLYMED.NS
Cost Of Revenue,2024-03-31 00:00:00,4826076000.0,POLYMED.NS
Total Revenue,2024-03-31 00:00:00,13757963000.0,POLYMED.NS
Operating Revenue,2024-03-31 00:00:00,13757963000.0,POLYMED.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,-10004584.8,POLYMED.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.2471,POLYMED.NS
Normalized EBITDA,2023-03-31 00:00:00,3072501000.0,POLYMED.NS
Total Unusual Items,2023-03-31 00:00:00,-40488000.0,POLYMED.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,-40488000.0,POLYMED.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,1792825000.0,POLYMED.NS
Reconciled Depreciation,2023-03-31 00:00:00,571668000.0,POLYMED.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,5093215000.0,POLYMED.NS
EBITDA,2023-03-31 00:00:00,3032013000.0,POLYMED.NS
EBIT,2023-03-31 00:00:00,2460345000.0,POLYMED.NS
Net Interest Income,2023-03-31 00:00:00,-48834000.0,POLYMED.NS
Interest Expense,2023-03-31 00:00:00,85431000.0,POLYMED.NS
Interest Income,2023-03-31 00:00:00,59740000.0,POLYMED.NS
Normalized Income,2023-03-31 00:00:00,1823308415.2,POLYMED.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,1792825000.0,POLYMED.NS
Total Expenses,2023-03-31 00:00:00,8908082000.0,POLYMED.NS
Rent Expense Supplemental,2023-03-31 00:00:00,19296000.0,POLYMED.NS
Diluted Average Shares,2023-03-31 00:00:00,96020945.0,POLYMED.NS
Basic Average Shares,2023-03-31 00:00:00,95916495.0,POLYMED.NS
Diluted EPS,2023-03-31 00:00:00,18.67,POLYMED.NS
Basic EPS,2023-03-31 00:00:00,18.69,POLYMED.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,1792825000.0,POLYMED.NS
Net Income Common Stockholders,2023-03-31 00:00:00,1792825000.0,POLYMED.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,POLYMED.NS
Net Income,2023-03-31 00:00:00,1792825000.0,POLYMED.NS
Minority Interests,2023-03-31 00:00:00,0.0,POLYMED.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,1792825000.0,POLYMED.NS
Net Income Continuous Operations,2023-03-31 00:00:00,1792825000.0,POLYMED.NS
Tax Provision,2023-03-31 00:00:00,582089000.0,POLYMED.NS
Pretax Income,2023-03-31 00:00:00,2374914000.0,POLYMED.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,32976000.0,POLYMED.NS
Special Income Charges,2023-03-31 00:00:00,-419000.0,POLYMED.NS
Other Special Charges,2023-03-31 00:00:00,-1003000.0,POLYMED.NS
Write Off,2023-03-31 00:00:00,1422000.0,POLYMED.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-48834000.0,POLYMED.NS
Total Other Finance Cost,2023-03-31 00:00:00,23143000.0,POLYMED.NS
Interest Expense Non Operating,2023-03-31 00:00:00,85431000.0,POLYMED.NS
Interest Income Non Operating,2023-03-31 00:00:00,59740000.0,POLYMED.NS
Operating Income,2023-03-31 00:00:00,2178500000.0,POLYMED.NS
Operating Expense,2023-03-31 00:00:00,3814867000.0,POLYMED.NS
Other Operating Expenses,2023-03-31 00:00:00,721760000.0,POLYMED.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,571668000.0,POLYMED.NS
Amortization,2023-03-31 00:00:00,29194000.0,POLYMED.NS
Depreciation Income Statement,2023-03-31 00:00:00,542474000.0,POLYMED.NS
Research And Development,2023-03-31 00:00:00,178025000.0,POLYMED.NS
Selling General And Administration,2023-03-31 00:00:00,380851000.0,POLYMED.NS
Selling And Marketing Expense,2023-03-31 00:00:00,205118000.0,POLYMED.NS
General And Administrative Expense,2023-03-31 00:00:00,175733000.0,POLYMED.NS
Rent And Landing Fees,2023-03-31 00:00:00,19296000.0,POLYMED.NS
Gross Profit,2023-03-31 00:00:00,5993367000.0,POLYMED.NS
Cost Of Revenue,2023-03-31 00:00:00,5093215000.0,POLYMED.NS
Total Revenue,2023-03-31 00:00:00,11086582000.0,POLYMED.NS
Operating Revenue,2023-03-31 00:00:00,11086582000.0,POLYMED.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,23940665.6,POLYMED.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.2528,POLYMED.NS
Normalized EBITDA,2022-03-31 00:00:00,2434507000.0,POLYMED.NS
Total Unusual Items,2022-03-31 00:00:00,94702000.0,POLYMED.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,94702000.0,POLYMED.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,1465060000.0,POLYMED.NS
Reconciled Depreciation,2022-03-31 00:00:00,539522000.0,POLYMED.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,4332255000.0,POLYMED.NS
EBITDA,2022-03-31 00:00:00,2529209000.0,POLYMED.NS
EBIT,2022-03-31 00:00:00,1989687000.0,POLYMED.NS
Net Interest Income,2022-03-31 00:00:00,-38722000.0,POLYMED.NS
Interest Expense,2022-03-31 00:00:00,37238000.0,POLYMED.NS
Interest Income,2022-03-31 00:00:00,22913000.0,POLYMED.NS
Normalized Income,2022-03-31 00:00:00,1394298665.6,POLYMED.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,1465060000.0,POLYMED.NS
Total Expenses,2022-03-31 00:00:00,7528345000.0,POLYMED.NS
Rent Expense Supplemental,2022-03-31 00:00:00,22357000.0,POLYMED.NS
Diluted Average Shares,2022-03-31 00:00:00,95964194.0,POLYMED.NS
Basic Average Shares,2022-03-31 00:00:00,95888694.0,POLYMED.NS
Diluted EPS,2022-03-31 00:00:00,15.27,POLYMED.NS
Basic EPS,2022-03-31 00:00:00,15.28,POLYMED.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,1465060000.0,POLYMED.NS
Net Income Common Stockholders,2022-03-31 00:00:00,1465060000.0,POLYMED.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,POLYMED.NS
Net Income,2022-03-31 00:00:00,1465060000.0,POLYMED.NS
Minority Interests,2022-03-31 00:00:00,0.0,POLYMED.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,1465060000.0,POLYMED.NS
Net Income Continuous Operations,2022-03-31 00:00:00,1465060000.0,POLYMED.NS
Tax Provision,2022-03-31 00:00:00,487389000.0,POLYMED.NS
Pretax Income,2022-03-31 00:00:00,1952449000.0,POLYMED.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,36518000.0,POLYMED.NS
Special Income Charges,2022-03-31 00:00:00,-1301000.0,POLYMED.NS
Other Special Charges,2022-03-31 00:00:00,-5305000.0,POLYMED.NS
Write Off,2022-03-31 00:00:00,6606000.0,POLYMED.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-38722000.0,POLYMED.NS
Total Other Finance Cost,2022-03-31 00:00:00,24397000.0,POLYMED.NS
Interest Expense Non Operating,2022-03-31 00:00:00,37238000.0,POLYMED.NS
Interest Income Non Operating,2022-03-31 00:00:00,22913000.0,POLYMED.NS
Operating Income,2022-03-31 00:00:00,1640534000.0,POLYMED.NS
Operating Expense,2022-03-31 00:00:00,3196090000.0,POLYMED.NS
Other Operating Expenses,2022-03-31 00:00:00,559930000.0,POLYMED.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,539522000.0,POLYMED.NS
Amortization,2022-03-31 00:00:00,26784000.0,POLYMED.NS
Depreciation Income Statement,2022-03-31 00:00:00,512738000.0,POLYMED.NS
Research And Development,2022-03-31 00:00:00,187711000.0,POLYMED.NS
Selling General And Administration,2022-03-31 00:00:00,322396000.0,POLYMED.NS
Selling And Marketing Expense,2022-03-31 00:00:00,150766000.0,POLYMED.NS
General And Administrative Expense,2022-03-31 00:00:00,171630000.0,POLYMED.NS
Rent And Landing Fees,2022-03-31 00:00:00,22357000.0,POLYMED.NS
Gross Profit,2022-03-31 00:00:00,4836624000.0,POLYMED.NS
Cost Of Revenue,2022-03-31 00:00:00,4332255000.0,POLYMED.NS
Total Revenue,2022-03-31 00:00:00,9168879000.0,POLYMED.NS
Operating Revenue,2022-03-31 00:00:00,9168879000.0,POLYMED.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,POLYMED.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,POLYMED.NS
Normalized EBITDA,2021-03-31 00:00:00,,POLYMED.NS
Total Unusual Items,2021-03-31 00:00:00,,POLYMED.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,POLYMED.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,POLYMED.NS
Reconciled Depreciation,2021-03-31 00:00:00,,POLYMED.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,POLYMED.NS
EBITDA,2021-03-31 00:00:00,,POLYMED.NS
EBIT,2021-03-31 00:00:00,,POLYMED.NS
Net Interest Income,2021-03-31 00:00:00,,POLYMED.NS
Interest Expense,2021-03-31 00:00:00,,POLYMED.NS
Interest Income,2021-03-31 00:00:00,33726000.0,POLYMED.NS
Normalized Income,2021-03-31 00:00:00,,POLYMED.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,POLYMED.NS
Total Expenses,2021-03-31 00:00:00,,POLYMED.NS
Rent Expense Supplemental,2021-03-31 00:00:00,22191000.0,POLYMED.NS
Diluted Average Shares,2021-03-31 00:00:00,89155423.0,POLYMED.NS
Basic Average Shares,2021-03-31 00:00:00,89083537.0,POLYMED.NS
Diluted EPS,2021-03-31 00:00:00,15.24,POLYMED.NS
Basic EPS,2021-03-31 00:00:00,15.25,POLYMED.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,POLYMED.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,POLYMED.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,POLYMED.NS
Net Income,2021-03-31 00:00:00,,POLYMED.NS
Minority Interests,2021-03-31 00:00:00,0.0,POLYMED.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,POLYMED.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,POLYMED.NS
Tax Provision,2021-03-31 00:00:00,,POLYMED.NS
Pretax Income,2021-03-31 00:00:00,,POLYMED.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,POLYMED.NS
Special Income Charges,2021-03-31 00:00:00,,POLYMED.NS
Other Special Charges,2021-03-31 00:00:00,-72000.0,POLYMED.NS
Write Off,2021-03-31 00:00:00,1799000.0,POLYMED.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,POLYMED.NS
Total Other Finance Cost,2021-03-31 00:00:00,29028000.0,POLYMED.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,POLYMED.NS
Interest Income Non Operating,2021-03-31 00:00:00,33726000.0,POLYMED.NS
Operating Income,2021-03-31 00:00:00,,POLYMED.NS
Operating Expense,2021-03-31 00:00:00,,POLYMED.NS
Other Operating Expenses,2021-03-31 00:00:00,,POLYMED.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,POLYMED.NS
Amortization,2021-03-31 00:00:00,24988000.0,POLYMED.NS
Depreciation Income Statement,2021-03-31 00:00:00,,POLYMED.NS
Research And Development,2021-03-31 00:00:00,,POLYMED.NS
Selling General And Administration,2021-03-31 00:00:00,294585000.0,POLYMED.NS
Selling And Marketing Expense,2021-03-31 00:00:00,126279000.0,POLYMED.NS
General And Administrative Expense,2021-03-31 00:00:00,168306000.0,POLYMED.NS
Rent And Landing Fees,2021-03-31 00:00:00,22191000.0,POLYMED.NS
Gross Profit,2021-03-31 00:00:00,,POLYMED.NS
Cost Of Revenue,2021-03-31 00:00:00,,POLYMED.NS
Total Revenue,2021-03-31 00:00:00,,POLYMED.NS
Operating Revenue,2021-03-31 00:00:00,,POLYMED.NS
